ArriVent BioPharma Inc. Common Stock (AVBP)
Stock · NASDAQ · Health Care
$16.66as of 10/16/2026
Price chart
Active signals
AVBP Signal Track Record
How signals performed across all stocks →What AVBP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 19 | +4.5% | 58% | October 6, 2026 |
| Bollinger Band Breakdown | 9 | +2.8% | 56% | October 6, 2026 |
| Bollinger Band Breakout | 9 | -5.1% | 44% | June 4, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +9.3% | 75% | March 30, 2026 |
| Any 20-session window (baseline) | -1.1% | 48% |
Computed by MarketWall from daily closing prices since November 8, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-sm…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 77
- Website
- arrivent.com/
Fundamentals
- 1-day range
- $16.49$17.23
- Market cap
- $1.44B
- P/E (trailing)
- —
- P/E (forward)
- -4.32
- EPS (trailing)
- $-3.67
- Dividend yield
- —
- Beta
- 1.44
- Avg. volume
- 1.00M
Forecasts
9 analyst ratings
ArriVent BioPharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AVBPArriVent BioPharma Inc. Common Stock$16.66▼ 0.77%Market cap $1.44BP/E —$11.36$35.83
- PAHCPhibro Animal Health Corporation Class A Common Stock$38.82▲ 2.21%Market cap $1.44BP/E 15.44$28.25$60.08
- XNCRXencor Inc. Common Stock$22.85▼ 4.79%Market cap $1.48BP/E —$10.38$30.61
- HROWHarrow Inc. Common Stock$27.28▼ 5.11%Market cap $1.49BP/E —$26.96$54.85
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
- ORICOric Pharmaceuticals Inc. Common Stock$12.35▼ 3.29%Market cap $1.34BP/E —$7.23$14.68
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVBP ArriVent BioPharma Inc. Common Stock | $1.44B | — | $16.66 | ▼ 0.77% | $11.36$35.83 |
| PAHC Phibro Animal Health Corporation Class A Common Stock | $1.44B | 15.44 | $38.82 | ▲ 2.21% | $28.25$60.08 |
| XNCR Xencor Inc. Common Stock | $1.48B | — | $22.85 | ▼ 4.79% | $10.38$30.61 |
| HROW Harrow Inc. Common Stock | $1.49B | — | $27.28 | ▼ 5.11% | $26.96$54.85 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
| ORIC Oric Pharmaceuticals Inc. Common Stock | $1.34B | — | $12.35 | ▼ 3.29% | $7.23$14.68 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Targetbenzinga · 10/16/2026
- Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · 10/8/2026
- HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27Benzinga · 10/8/2026
- Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial failsYahoo · 10/8/2026
- Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20Benzinga · 10/7/2026
- ArriVent’s stock plummets on Phase III NSCLC trial failureYahoo · 10/7/2026
- Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18Benzinga · 10/7/2026
- BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On WednesdayBenzinga · 10/7/2026
- Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18Benzinga · 10/7/2026
Insider Activity
Insider Actions →- Parsey Merdad · June 18, 2026 · Grant13.6K
- Nolet Chris · June 18, 2026 · Grant13.6K
- Hohneker John · June 18, 2026 · Grant13.6K
- Peterson Kristine · June 18, 2026 · Grant13.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 42.06M
- Total value held
- $966.29M
- Institutional holders
- 133
- Unknown4.40M
- Unknown4.15M
- Unknown3.93M
- Unknown3.03M
- Unknown3.02M
- Unknown2.53M
- Unknown1.97M
- Unknown1.94M
- Unknown1.70M
- Unknown1.53M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AVBP Included in Whale Activity Among 10 Health Care Stocks
AVBP was listed among ten health‑care stocks that saw significant whale activity during today's trading session. The move indicates that large institutional investors are actively buying shares of the company. This activity could signal increased confidence in AVBP's prospects. The stock remains within its 52‑week range and near the midpoint of analyst target levels.
AVBP Included in Whale Activity Among 10 Health Care Stocks. AVBP was listed among ten health‑care stocks that saw significant whale activity during today's trading session. The move indicates that large institutional investors are actively buying shares of the company. This activity could signal increased confidence in AVBP's prospects. The stock remains within its 52‑week range and near the midpoint of analyst target levels.